Combination products are being developed in response to the increasing demands of patients requiring more advanced and more effective treatments
There are less formal regulations governing combination products because the field is relatively new
The US Food and Drug Administration’s Office of Combination Products was created in 2002 to oversee the regulatory lifecycle of combination products
Major market growth is projected for combination products over the next decade both in the US and abroad
The drivers for combination products include patent life extension, more products and technologies...
This content is only available to IVT members.
Get help maintaining your knowledge in GMP - Medical Devices. Read More!
If you are already a member and you do not have access to this article, upgrade your membership.
Need help? Read our FAQs.
